Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-702X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Psychological impact of anti-VEGF treatments for wet macular degeneration—a review ; day:4 ; month:6 ; year:2016 ; pages:1-8
Graefe's archive for clinical and experimental ophthalmology ; (4.6.2016), 1-8
- Urheber
-
Senra, Hugo
- Beteiligte Personen und Organisationen
-
Ali, Zaria
Balaskas, Konstantinos
Aslam, Tariq
SpringerLink (Online service)
- DOI
-
10.1007/s00417-016-3384-0
- URN
-
urn:nbn:de:1111-201606057802
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Senra, Hugo
- Ali, Zaria
- Balaskas, Konstantinos
- Aslam, Tariq
- SpringerLink (Online service)
Ähnliche Objekte (12)
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
Anti-VEGF for the management of diabetic macular edema
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Anti-VEGF : 13 tables
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema
Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)
Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
Future of anti-VEGF: biosimilars and biobetters
Book Review: Anti-VEGF Use in Ophthalmology
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
Anti-VEGF for the management of diabetic macular edema
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Anti-VEGF : 13 tables
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema
Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)
Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
Future of anti-VEGF: biosimilars and biobetters
Book Review: Anti-VEGF Use in Ophthalmology
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
Anti-VEGF for the management of diabetic macular edema
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Anti-VEGF : 13 tables
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema
Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)
Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
Future of anti-VEGF: biosimilars and biobetters